An Open-label, Randomized, Single Dose, Crossover, Pivotal Bioequivalence Study of Fixed-dose Combination Tablets of Dolutegravir and Lamivudine Versus Dolutegravir and Lamivudine Single Entities and Food Effect Assessment in Healthy Volunteers

Trial Profile

An Open-label, Randomized, Single Dose, Crossover, Pivotal Bioequivalence Study of Fixed-dose Combination Tablets of Dolutegravir and Lamivudine Versus Dolutegravir and Lamivudine Single Entities and Food Effect Assessment in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Dolutegravir/lamivudine (Primary) ; Dolutegravir; Lamivudine
  • Indications HIV infections
  • Focus Pharmacokinetics; Registrational
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 05 Sep 2017 Status changed from recruiting to completed.
    • 03 May 2017 Status changed from not yet recruiting to recruiting.
    • 15 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top